However, current decisions regarding treatment escalation or de-escalation are still primarily based on traditional parameters like tumor size, lymph node involvement, hormone receptor expression, and response to neoadjuvant therapy (pCR achievement or not). The gene discussed is NR4A1; the disease is neoplasm.